THERAPY DOSSIER · th-7c7a0e27ef6b

Granulocyte macrophage-colony stimulating factor (GM-CSF)

Biologic · AGONIST of the GM-CSF receptor (alpha subunit binding site); direct interaction with disease efficacy.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: AGONIST of the GM-CSF receptor (alpha subunit binding site); direct interaction with disease efficacy.
Target: CHEMBL2364169 (GM-CSF receptor)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 1991
Development stage: Not recorded
ChEMBL record: CHEMBL1201670 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: GM-CSF; rhu GM-CSF; Leukine; Sargramostim
Note: Not recorded

Clinical trials 6

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02149225 ↗Injury indicationPHASE1completed

Actively Personalized Peptide Vaccinations Plus Immunomodulators (Poly-ICLC and GM-CSF) in Newly Diagnosed Glioblastoma

Glioblastoma

Enrolment: 16 · Results not recorded

NCT03597347 ↗PHASE2terminated

Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Mycobacterium Infections, Nontuberculous · Cystic Fibrosis

Enrolment: 14 · Results not recorded

NCT00022230 ↗PHASE1/PHASE2withdrawn

TAC Chemotherapy With Activated T Cells, IL-2 and GM-CSF for High Risk Breast Cancer

Breast Cancer

Enrolment: 0 · Results not recorded

NCT05501340 ↗PHASE1/PHASE2unknown

PRaG (PD-1 Inhibitor, Radiotherapy and GM-CSF) for Advanced Refractory Solid Tumors With Malignant Ascites

Malignant Ascites

Enrolment: 40 · Results not recorded

NCT00027807 ↗PHASE1completed

Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF

Breast Cancer

Enrolment: 6 · Results not recorded

NCT00001269 ↗PHASE1completed

FLAC Plus GM-CSF Plus Dose Escalation of IL-3 in Metastatic Breast Cancer

Breast Neoplasms · Neoplasm Metastasis

Enrolment: 100 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28274846 ↗2017Mixed findings

Acute granulocyte macrophage-colony stimulating factor treatment modulates neuroinflammatory processes and promotes tactile recovery after spinal cord injury.

RatSpinal cord injuryHemisection / partialWistarmaleone hour after hemisection

Model: C4 to C5 medio-lateral spinal cord hemisection

GM-CSF promoted cortical reactivation and recovery of tactile abilities and transiently reduced pro-inflammatory cytokines and glial scarring, but did not influence motor performance.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…